2018
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis
Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Myint A, Smith FM, Saunders MP, Scott N, O'Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Julião G, Perez R, Renehan AG. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. The Lancet Gastroenterology & Hepatology 2018, 3: 825-836. PMID: 30318451, DOI: 10.1016/s2468-1253(18)30301-7.Peer-Reviewed Original ResearchConceptsClinical complete responseIndividual participant dataComplete responseLocal regrowthRectal cancerCumulative incidenceParticipant dataNeoadjuvant chemoradiotherapyHazard ratioSustained clinical complete responseProportion of patientsCenter heterogeneityRecent systematic reviewCox frailty modelStage cT1CT2 tumorsMajor surgeryPrimary outcomeTreatment characteristicsChemoradiotherapyLower riskPatientsStudy heterogeneitySystematic reviewNovel management strategies
2015
HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era
Grew D, Bitterman D, Leichman CG, Leichman L, Sanfilippo N, Moore HG, Du K. HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era. Diseases Of The Colon & Rectum 2015, 58: 1130-1136. PMID: 26544809, DOI: 10.1097/dcr.0000000000000476.Peer-Reviewed Original ResearchConceptsHIV-negative patientsHIV-positive patientsActive antiretroviral therapy (HAART) eraAntiretroviral therapy eraColostomy-free survivalOverall survival rateAnal cancerSurvival rateTherapy eraMultivariate analysisColostomy-free survival ratesLocal recurrence-free survivalDistant metastasis-free survivalRetrospective chart reviewSmall patient numbersRecurrence-free survivalMetastasis-free survivalOutpatient oncology clinicsLarge academic centerDefinitive chemoradiationDefinitive chemoradiotherapyChart reviewOverall survivalPatient characteristicsHIV infectionRadiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data
Modrek AS, Hsu HC, Leichman CG, Du KL. Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data. Radiation Oncology 2015, 10: 101. PMID: 25902707, PMCID: PMC4464878, DOI: 10.1186/s13014-015-0411-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyDigestive System Surgical ProceduresFemaleHumansKaplan-Meier EstimateMaleMiddle AgedOrganoplatinum CompoundsProportional Hazards ModelsRectal NeoplasmsRetrospective StudiesSEER ProgramSurvival AnalysisUnited StatesConceptsRadiation therapyOverall survivalRectal cancerSurveillance EpidemiologyCell carcinomaSEER dataMultivariate Cox proportional hazards modelCox proportional hazards modelBackgroundSmall cell carcinomaMethodsThe SEER databaseCancer-directed therapyEnd Results (SEER) databaseUnadjusted hazard ratioEnd Results (SEER) dataKaplan-Meier methodOverall survival rateYear of diagnosisSmall cell carcinomaSignificant survival advantagePearson's chi-square testProportional hazards modelOnly significant factorChi-square testChemotherapy usageLocoregional cases
2011
Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials
Du KL, Bae K, Movsas B, Yan Y, Bryan C, Bruner DW. Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials. Supportive Care In Cancer 2011, 20: 1317-1325. PMID: 21720747, DOI: 10.1007/s00520-011-1219-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsMaleMarital StatusMiddle AgedPrognosisProportional Hazards ModelsProstatic NeoplasmsRacial GroupsRandomized Controlled Trials as TopicSurvival RateTime FactorsTreatment FailureTreatment OutcomeConceptsPathologic prognostic factorsPrognostic factorsProportional hazards modelOverall survivalMedian timeSociodemographic factorsWhite patientsCancer outcomesPrognostic indicatorProstate cancerMarital statusImproved prostate cancer outcomesHigh-risk cancer patientsGray proportional hazards modelsCommon visceral cancerOutcomes of patientsBiochemical failure rateCumulative incidence methodSignificant prognostic factorsCancer-related outcomesKaplan-Meier methodProstate cancer outcomesGroup of patientsNon-white patientsProstate cancer risk
2010
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma
Du KL, Both S, Friedberg JS, Rengan R, Hahn SM, Cengel KA. Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biology & Therapy 2010, 10: 425-429. PMID: 20699634, DOI: 10.4161/cbt.10.5.12616.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaPlanning treatment volumeExtrapleural pneumonectomyPleural mesotheliomaRadiation therapyImproved local controlMedian radiation doseFuture prospective analysesTreatment of mesotheliomaNew treatment modalitiesIntraoperative photodynamic therapyQuality of lifePhotodynamic therapyIntraoperative adjuvantMultimodality therapyRadiation pneumonitisRespiratory failureSurgical debulkingContralateral lungMPM patientsDoses of radiationMechanical ventilationMultimodality approachLung toxicityTreatment modalities
2007
Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome
Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome. International Journal Of Radiation Oncology • Biology • Physics 2007, 69: 1024-1031. PMID: 17967299, PMCID: PMC2737259, DOI: 10.1016/j.ijrobp.2007.04.067.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaPatient outcomesNeck squamous cell tumorsNeck squamous cell carcinomaEvent-free survival timeShorter event-free survival timePositron emission tomographic studiesSquamous cell tumorsLevels of hypoxiaEmission tomographic studiesNodal statusOverall survivalTreatment regimenPrognostic significanceCell tumorsPrimary headMajority of cellsSurvival timeOral cavityHypoxia markersQuantitative immunohistochemistryEF5 bindingSevere hypoxiaPatients
2006
Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer
Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM. Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer. Lasers In Surgery And Medicine 2006, 38: 427-434. PMID: 16788929, DOI: 10.1002/lsm.20341.Peer-Reviewed Original ResearchConceptsInterstitial photodynamic therapyProstate adenocarcinomaProstate cancerPhotodynamic therapyRecurrent prostate adenocarcinomaSolid organ diseaseSubsequent tissue necrosisOrgan diseaseDrug levelsPreclinical studiesClinical experienceSTUDY DESIGN/MATERIALSTissue necrosisDose distributionDESIGN/MATERIALSPhase IAdenocarcinomaHuman subjectsProstateCancerTreatmentUniversity of PennsylvaniaDose variationComprehensive treatmentPatients